aspirin has been researched along with Angina Pectoris, Stable in 18 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 5.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
| "Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone." | 5.24 | Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017) |
| " Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| " Researchers followed up with participants for one month after treatment to determine whether adverse events (AEs) or adverse drug reactions (ADRs) such as bleeding tendency occurred." | 3.01 | Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial. ( Chai, Y; Chen, K; Gong, Y; Li, J; Lyu, J; Lyu, W; Wang, L; Wen, Z; Xie, Y; Xue, M; Yao, P; Zhang, Y, 2021) |
| "Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI." | 2.77 | Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012) |
| "Intermittent left bundle branch block is a conduction disturbance that has been described to be associated with myocardial bridges and cardiac memory." | 1.51 | Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report. ( Ibarrola, M, 2019) |
| "Biomolecular network analysis was used to predict the mechanism of Salvianolate injection combined with aspirin for the treatment of stable angina pectoris(SAP)." | 1.43 | [Mechanism of Salvianolate injection combined with aspirin in treatment of stable angina pectoris based on biomolecules network]. ( Li, Y; Wang, LX; Xie, YM, 2016) |
| "Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 1.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
| "Sarpogrelate was administered to 22 of 33 patients with SEA in addition to aspirin therapy, and platelet aggregation, plasma serotonin concentration, and plasma plasminogen activator inhibitor (PAI) activity were measured before and 1 week after administration." | 1.37 | Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. ( Kajiwara, I; Miyamoto, S; Ogawa, H; Soejima, H, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (94.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Lyu, J | 1 |
| Xue, M | 1 |
| Li, J | 2 |
| Lyu, W | 1 |
| Wen, Z | 1 |
| Yao, P | 1 |
| Zhang, Y | 1 |
| Gong, Y | 1 |
| Xie, Y | 1 |
| Chen, K | 1 |
| Wang, L | 1 |
| Chai, Y | 1 |
| Cheng, G | 1 |
| Shan, XF | 1 |
| Wang, XL | 1 |
| Dong, WW | 1 |
| Li, Z | 1 |
| Liu, XH | 1 |
| Zhang, W | 1 |
| Xing, K | 1 |
| Chang, FJ | 1 |
| Li, Y | 1 |
| Wang, LX | 1 |
| Xie, YM | 1 |
| Ibarrola, M | 1 |
| Jiang, Z | 1 |
| Wu, H | 1 |
| Duan, Z | 1 |
| Wang, Z | 1 |
| Hu, K | 1 |
| Ye, F | 1 |
| Zhang, Z | 1 |
| Mizia-Stec, K | 3 |
| Mizia, M | 2 |
| Haberka, M | 3 |
| Lasota, B | 3 |
| Gieszczyk-Strózik, K | 1 |
| Chmiel, A | 2 |
| Najda, J | 2 |
| Gąsior, Z | 3 |
| Kyrcz-Krzemień, S | 3 |
| Legrand, V | 1 |
| Cuisset, T | 1 |
| Chenu, P | 1 |
| Vrolix, M | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 1 |
| Claeys, MJ | 1 |
| Magne, J | 1 |
| Barbato, E | 1 |
| Wijns, W | 1 |
| Arima, Y | 1 |
| Hokimoto, S | 1 |
| Akasaka, T | 1 |
| Mizobe, K | 1 |
| Kaikita, K | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Ogawa, H | 2 |
| Rossini, R | 1 |
| Musumeci, G | 1 |
| Capodanno, D | 1 |
| Lettieri, C | 1 |
| Limbruno, U | 1 |
| Tarantini, G | 1 |
| Russo, N | 1 |
| Calabria, P | 1 |
| Romano, M | 1 |
| Inashvili, A | 1 |
| Sirbu, V | 1 |
| Guagliumi, G | 1 |
| Valsecchi, O | 1 |
| Senni, M | 1 |
| Gavazzi, A | 1 |
| Angiolillo, DJ | 1 |
| Konishi, A | 1 |
| Shinke, T | 1 |
| Otake, H | 1 |
| Takaya, T | 1 |
| Osue, T | 1 |
| Kinutani, H | 1 |
| Kuroda, M | 1 |
| Takahashi, H | 1 |
| Terashita, D | 1 |
| Hirata, K | 1 |
| Rousan, TA | 1 |
| Mathew, ST | 1 |
| Thadani, U | 1 |
| Stefanescu Schmidt, AC | 1 |
| Kereiakes, DJ | 1 |
| Cutlip, DE | 1 |
| Yeh, RW | 1 |
| D'Agostino, RB | 1 |
| Massaro, JM | 1 |
| Hsieh, WH | 1 |
| Mauri, L | 1 |
| Kajiwara, I | 1 |
| Soejima, H | 1 |
| Miyamoto, S | 1 |
| Motoda, C | 1 |
| Ueda, H | 1 |
| Hayashi, Y | 1 |
| Toyofuku, M | 1 |
| Okimoto, T | 1 |
| Otsuka, M | 1 |
| Tamekiyo, H | 1 |
| Kawase, T | 1 |
| Kihara, Y | 1 |
| Kunecki, M | 1 |
| Gieszczyk, K | 1 |
| Isshiki, T | 1 |
| Kimura, T | 1 |
| Ueno, T | 1 |
| Nakamura, M | 1 |
| Igarashi, K | 1 |
| Yokoi, H | 1 |
| Kobayashi, M | 1 |
| Ikari, Y | 1 |
| Viswanathan, GN | 1 |
| Marshall, SM | 1 |
| Schechter, CB | 1 |
| Balasubramaniam, K | 1 |
| Badimon, JJ | 1 |
| Zaman, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial[NCT02694848] | Phase 4 | 120 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Effectiveness and Safety of Danshen Injection for Acute Kidney Injury in Primary Nephrotic Syndrome[NCT06071533] | 441 participants (Actual) | Observational | 2012-01-01 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
1 review available for aspirin and Angina Pectoris, Stable
| Article | Year |
|---|---|
Drug Therapy for Stable Angina Pectoris.
Topics: Angina, Stable; Aspirin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Vasodilator Agents | 2017 |
8 trials available for aspirin and Angina Pectoris, Stable
| Article | Year |
|---|---|
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Topics: Aged; Angina, Stable; Aspirin; Cardiovascular Agents; Creatinine; Depsides; Drug Therapy, Combinatio | 2021 |
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Topics: Aged; Angina, Stable; Aspirin; Cardiovascular Agents; Creatinine; Depsides; Drug Therapy, Combinatio | 2021 |
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Topics: Aged; Angina, Stable; Aspirin; Cardiovascular Agents; Creatinine; Depsides; Drug Therapy, Combinatio | 2021 |
Clinical effectiveness and safety of salvia miltiorrhiza depside salt combined with aspirin in patients with stable angina pectoris: A multicenter, pragmatic, randomized controlled trial.
Topics: Aged; Angina, Stable; Aspirin; Cardiovascular Agents; Creatinine; Depsides; Drug Therapy, Combinatio | 2021 |
N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Docosahexaenoic Acids; Drug Combination | 2013 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angina, Stable; Aspirin; Drug-Eluting Stents; Female | 2012 |
Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
9 other studies available for aspirin and Angina Pectoris, Stable
| Article | Year |
|---|---|
Endothelial damage effects of circulating microparticles from patients with stable angina are reduced by aspirin through ERK/p38 MAPKs pathways.
Topics: Angina, Stable; Animals; Aorta, Thoracic; Aspirin; Cell-Derived Microparticles; Endothelium, Vascula | 2017 |
[Mechanism of Salvianolate injection combined with aspirin in treatment of stable angina pectoris based on biomolecules network].
Topics: Angina, Stable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Humans; Plant Ext | 2016 |
Multiple myocardial bridges associated with left-ventricular dysfunction, intermittent left bundle branch block, and cardiac memory: A case report.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Aspirin; Bundle-Branch Block; Cardiotonic Agents; Compu | 2019 |
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control | 2013 |
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Cytoc | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Obesity; Percutaneous | 2015 |
Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis.
Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Drug Therapy, Com | 2016 |
Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
Topics: Adult; Aged; Angina, Stable; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Pl | 2011 |